Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE 60 versus GASTROMARK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE 60 versus GASTROMARK.
DIATRIZOATE-60 vs GASTROMARK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Gastromark (ferumoxsil) is an oral superparamagnetic contrast agent used in MRI. It contains iron oxide particles that create local magnetic field inhomogeneities, reducing T2* signal in the gastrointestinal tract, thereby improving visualization of abdominal organs by darkening the bowel lumen.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
Orally, 30-60 mL of a 1% suspension (300-600 mg iron) diluted in water or juice, given 12-24 hours prior to MRI examination; may be repeated if necessary.
None Documented
None Documented
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Terminal elimination half-life: 3.1-3.5 hours; clinical context: supports rapid clearance from the body after imaging.
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
Renal: 23-31% as intact compound; fecal: 69-77% via biliary elimination; very little metabolism.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent